Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FY23D
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,715
Award facts
- Contract value 100% obligated
- $22,714.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,714.80 delivery order to DMS Pharmaceutical Group Inc. on September 8, 2025, for the supply of Nucala 100 mg/ml auto-injectors, with an ultimate completion date of September 9, 2025. This firm fixed-price delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at $499,999,999 and valid through November 2026. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its status as a woman-owned small business. The place of performance is Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its primary operations.
DMS Pharmaceutical Group Inc. serves as a critical supplier within the federal pharmaceutical supply chain, specializing in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. The company's IDC with DLA under the SPE2DB program enables the agency to issue delivery orders for comprehensive pharmaceutical products supporting military health system requirements across global locations. Through this arrangement, DMS Pharmaceutical Group has consistently secured contracts covering an extensive portfolio of medical products, ranging from specialty medications and auto-injectors to oncology treatments and vaccines, positioning the firm as an essential provider for federal healthcare procurement.
Quick answers
Who was awarded contract SPE2DB25FY23D?
SPE2DB25FY23D was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 8, 2025.
How much is contract SPE2DB25FY23D worth?
The government has obligated $22,715 on SPE2DB25FY23D.
Is contract SPE2DB25FY23D an order under another contract?
Yes. SPE2DB25FY23D is a delivery order under SPE2DB22D9362, an indefinite delivery contract.
Was contract SPE2DB25FY23D competed?
The extent of competition for SPE2DB25FY23D was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award